|
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis |
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst) |
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai |
|
|
Honoraria - Eisai; Oncology Information Group |
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono |
|
|
Consulting or Advisory Role - Eisai |
Research Funding - BostonGene |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis |
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen |
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Ipsen |
Speakers' Bureau - Bristol-Myers Squibb; Ipsen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Pfizer; Roche; Sanofi |
Speakers' Bureau - Abbott; Acraf; Bristol-Myers Squibb; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Abbott; Acraf; Pfizer; Roche; Sanofi |
|
|
Stock and Other Ownership Interests - Nordic Nanovector (I) |
|
|
|
|
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Apyx Medical; ImmunoGen; Mallinckrodt; Seres Therapeutics; Sesen Bio; ZIOPHARM Oncology |
|
|
|
|
|
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst) |